Czech
Albanian
Arabic
Armenian
Azerbaijani
Belarusian
Bengali
Bosnian
Catalan
Czech
Danish
Deutsch
Dutch
English
Estonian
Finnish
Français
Greek
Haitian Creole
Hebrew
Hindi
Hungarian
Icelandic
Indonesian
Irish
Italian
Japanese
Korean
Latvian
Lithuanian
Macedonian
Mongolian
Norwegian
Persian
Polish
Portuguese
Romanian
Russian
Serbian
Slovak
Slovenian
Spanish
Swahili
Swedish
Turkish
Ukrainian
Vietnamese
Български
中文(简体)
中文(繁體)
Strana 1 z 101 Výsledek
Treatment of patients with advanced gastric carcinoma with the combination of etoposide plus oral tegafur modulated by uracil and leucovorin. A phase II study of the ONCOPAZ Cooperative Group.
Články mohou překládat pouze registrovaní uživatelé
Přihlášení Registrace
BACKGROUND
Both the biochemical modulation and the continuous administration of 5-fluorouracil (5-FU) have achieved promising results in patients with gastric carcinoma. Conversely, several studies on gastric carcinoma have demonstrated that the combination of etoposide (VP-16), leucovorin (LV), and
5-Fluorouracil, mitomycin-c, and polysaccharide-k versus uracil-ftorafur and polysaccharide-K as adjuvant chemoimmunotherapy for patients with locally advanced gastric cancer with curative resection.
Články mohou překládat pouze registrovaní uživatelé
Přihlášení Registrace
BACKGROUND
Despite the small but significant survival benefit of adjuvant chemotherapy in locally advanced gastric cancer (LAGC), the optimal regimen remains to be determined. We conducted a randomized trial comparing oral (PO) chemoimmunotherapy (CITX) with intravenous (IV) CITX in LAGC patients
A neonate with recurrent vomiting and generalized hypotonia diagnosed with a deficiency of dihydropyrimidine dehydrogenase.
Články mohou překládat pouze registrovaní uživatelé
Přihlášení Registrace
Deficiency of dihydropyrimidine dehydrogenase (DPD) is a rare inborn error of pyrimidine metabolism. To date, only about 50 patients are known worldwide. The clinical picture is varied and is not yet fully described. Most patients are diagnosed at the age of 1-3 years. We present a patient diagnosed
Prophylaxis of delayed nausea and vomiting after cancer chemotherapy.
Články mohou překládat pouze registrovaní uživatelé
Přihlášení Registrace
OBJECTIVE
To compare ondansetron and domperidone for treatment of delayed nausea/vomiting (DN/V) following highly emetogenic chemotherapy, after attaining total suppression of emesis on the day of chemotherapy by mean of ondansetron (combined with dexamethasone in the case of cisplatin-treated
Phase I dose escalation study of oxaliplatin combined with oral tegafur-uracil and leucovorin in patients with advanced gastric cancer.
Články mohou překládat pouze registrovaní uživatelé
Přihlášení Registrace
Our aim was to determine the dose-limiting toxicities (DLTs), maximum tolerated dose (MTD) and recommended dose of oxaliplatin combined with oral tegafur-uracil and leucovorin. Twenty-eight chemo-naive patients with advanced gastric cancer were enrolled. Oxaliplatin (55, 70, 85, 100 and 115 mg/m2)
[Clinical experience of tegafur-uracil (UFT) against bladder cancer and renal cell carcinoma].
Články mohou překládat pouze registrovaní uživatelé
Přihlášení Registrace
The safety of prolonged administration of UFT in which tegafur and uracil were mixed in a ratio of 1:4 in molar fraction was studied in 44 cases of bladder cancer and 10 cases of renal cell carcinoma. Daily doses of UFT were 300-600 mg, and average total doses administered were 102.0 g for bladder
Endocrine plus uracil/tegafur therapy for prostate cancer.
Články mohou překládat pouze registrovaní uživatelé
Přihlášení Registrace
A prospective, randomized clinical trial was conducted to evaluate the efficacy of endocrine chemotherapy with uracil and tegafur (in a molar ratio of 4:1 [UFT]) in patients with prostate cancer. The study included two treatment arms: endocrine plus UFT vs endocrine-only therapy. Of the 136 patients
Tegafur and uracil plus leucovorin in advanced colorectal cancer: a phase II trial.
Články mohou překládat pouze registrovaní uživatelé
Přihlášení Registrace
The objective of this study was to evaluate the activity and toxicity of tegafur and uracil (UFT; 1:4 molar ratio) plus leucovorin (LV) in patients with advanced colorectal cancer. One hundred forty-one patients were entered into the study. The treatment schedule consisted of UFT 300 mg/m2/day (in
High-dose oral tegafur-uracil maintenance therapy in patients with uterine cervical cancer.
Články mohou překládat pouze registrovaní uživatelé
Přihlášení Registrace
OBJECTIVE
The aim of this study was to determine the efficacy and toxicity of oral administration of tegafur-uracil (UFT) at a high dose, 600 mg/day, based on the tegafur dose, against uterine cervical cancer.
METHODS
This study consisted of a retrospective analysis. From April 1986 to March 1997,
[Combination chemotherapy with tegafur-uracil (UFT) and cisplatin (CDDP) for advanced gastric cancer. UFTP Study Group].
Články mohou překládat pouze registrovaní uživatelé
Přihlášení Registrace
An early phase II study of tegafur-uracil (UFT) combined with cisplatin (CDDP) was conducted in patients with advanced gastric cancer. UFT was administered orally for 28 consecutive days at a dose of 400 mg/m2 and CDDP was injected intravenously for 3 day at a dose of 30 mg/m2 over 8 hours every 4
A phase II study of epirubicin, cisplatin and uracil-tegafur for advanced gastric carcinoma.
Články mohou překládat pouze registrovaní uživatelé
Přihlášení Registrace
BACKGROUND
Due to its greater convenience, a combination of uracil and tegafur (referred to as UFT) taken orally is an attractive alternative to continuous intravenous (i.v.) 5-fluorouracil (5-FU) infusion. This phase II study assessed the response rate and toxicity profile of the combination of
Efficacy of oral tegafur modulation by uracil and leucovorin in advanced colorectal cancer. A phase II study.
Články mohou překládat pouze registrovaní uživatelé
Přihlášení Registrace
A phase II study was performed to assess the efficacy and toxicity of UFT (tegafur-uracil in the molar ratio 1:4) modulated with leucovorin (LV) in previously untreated patients with advanced colorectal carcinoma (CRC). 79 patients with measurable advanced colorectal cancer (CRC) and no prior
Concomitant administration of uracil-tegafur and leucovorin during adjuvant radiotherapy for locally advanced rectal cancer.
Články mohou překládat pouze registrovaní uživatelé
Přihlášení Registrace
OBJECTIVE
We report the feasibility and toxicity profile, and the impact on local control, disease-free survival and overall survival rates of our study which consisted of postoperative concurrent chemoradiotherapy, followed by adjuvant chemotherapy using uracil-tegafur (UFT)/leukovorin (LV) in
Phase II study of uracil-tegafur plus cisplatin in patients with previously untreated advanced non-small cell lung cancer.
Články mohou překládat pouze registrovaní uživatelé
Přihlášení Registrace
OBJECTIVE
A multi-institutional phase II trial combining uracil-tegafur (UFT) and cisplatin (CDDP) was conducted in patients with previously untreated advanced non-small cell lung cancer (NSCLC) to evaluate the safety and efficacy of this combined treatment regimen.
METHODS
The entry criteria for
Phase I study of oral uracil and Tegafur plus leucovorin and pelvic radiation in patients with recurrent rectal cancer.
Články mohou překládat pouze registrovaní uživatelé
Přihlášení Registrace
Continuous 5-fluorouracil (5-FU) infusion during radiation therapy is superior to the application of bolus 5-FU schedules. As an oral therapy, that provides prolonged fluoropyrimidine exposure, uracil and Tegafur (UFT) plus leucovorin (LV) has shown favorable activity with only moderate toxicity in
Nejúplnější databáze léčivých bylin podložená vědou
- Funguje v 55 jazycích
- Bylinné léky podporované vědou
- Rozpoznávání bylin podle obrázku
- Interaktivní mapa GPS - označte byliny na místě (již brzy)
- Přečtěte si vědecké publikace související s vaším hledáním
- Hledejte léčivé byliny podle jejich účinků
- Uspořádejte své zájmy a držte krok s novinkami, klinickými testy a patenty
Zadejte symptom nebo chorobu a přečtěte si o bylinách, které by vám mohly pomoci, napište bylinu a podívejte se na nemoci a příznaky, proti kterým se používá.
* Všechny informace vycházejí z publikovaného vědeckého výzkumu
